Evidence map›Paper›PMID 40897830›Full record

ArticleNPJ precision oncology2025

Enhanced metastasis risk prediction in cutaneous squamous cell carcinoma using deep learning and computational histopathology.

Emilia Peleva, Yue Chen, Bernhard Finke, Hasan Rizvi, Eugene Healy, Chester Lai, Paul Craig, William Rickaby, Christina Schoenherr, Craig Nourse and 5 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Emilia Peleva *Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK. emilia.peleva@nhs.net.
Yue Chen *Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK.
Bernhard FinkeCentre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK.
Hasan RizviPathology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Eugene HealyDermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK.
Chester LaiDermatopharmacology, Faculty of Medicine, University of Southampton, Southampton, UK.
Paul CraigCellular Pathology, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.
William RickabyCellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
Christina SchoenherrCancer Research UK Scotland Institute, Glasgow, UK.
Craig NourseCancer Research UK Scotland Institute, Glasgow, UK.
Charlotte ProbyDivision of Cancer Research, School of Medicine, University of Dundee, Dundee, UK.
Gareth J InmanCancer Research UK Scotland Institute, Glasgow, UK.
Irene M LeighBarts Centre for Squamous Cancer, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Catherine A HarwoodDermatology, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Jun WangCentre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK. j.a.wang@qmul.ac.uk.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the most common skin cancer with metastatic potential and development of metastases carries a poor prognosis. To address the need for reliable risk stratification, we developed cSCCNet, a deep learning model using digital pathology of primary cSCC to predict metastatic risk. A retrospective cohort of 227 primary cSCC from four centres is used for model development. cSCCNet automatically selects the tumour area in standard histopathological slides and then stratifies primary cSCC into high- vs. low-risk categories, with heatmaps indicating most predictive tiles contributing to explainability. On a 20% hold-out testing cohort, cSCCNet achieves an area under the curve (AUC) of 0.95 and 95% accuracy in predicting risk of metastasis, outperforming gene expression-based tools and clinicopathologic classifications. Multivariate analysis including common clinicopathologic classifications confirms cSCCNet as an independent predictor for metastasis, implying it identifies predictive features beyond known clinicopathologic risk factors. Histopathological analysis including multiplex immunohistochemistry suggests that tumour differentiation, acantholysis, desmoplasia, and the spatial localisation of lymphocytes relative to tumour tissue may be important in predicting risk of developing metastasis. Although further validation including prospective evaluation is required, cSCCNet has potential as a reliable and accurate tool for metastatic risk prediction that could be easily integrated into existing histopathology workflows.

Identifiers

PMID40897830
PMCPMC12405460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.